Search
MRK.US: First anti-IDO/PD1 data appears no better than current standard of care
Much anticipated IDO+PD1 combo data faces high hurlde...
IDO inhibition is one of many newer immunotherapies that are beginning to enter clinical trials. First anti PD1 Keytruda combination data with Incyte’s IDO inhibitor INCB024360 (epacadostat), which is thought to supress immune T‑ cells from killing cancer in Melanoma was presented this weekend, but appears not to be better than the standard of care...
